Head to head
Metformin plus rapamycin against Rapamycin
The combination against the single drug. This matters because metformin blunts some of the exercise and muscle adaptations people take rapamycin hoping to preserve, so the stack is not automatically the sum of its parts.
Column A
Metformin plus rapamycinMetformin plus rapamycin (Interventions Testing Program combination arm)
Fed together from 9 months, metformin 1,000 ppm and rapamycin 14 ppm extended median mouse lifespan 23 percent in both sexes. Metformin alone in the same cohort did nothing, there was no rapamycin-alone arm to compare against, and the ITP's own paper says the apparent extra benefit over historical rapamycin cohorts did not reach significance by its protocol test.
Column B
RapamycinRapamycin (Sirolimus, mTOR inhibitor)
An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity.
Side by side, on the facts we can check
| Attribute | Metformin plus rapamycin | Rapamycin |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Both drugs are FDA-approved for other indications (metformin for type 2 diabetes, rapamycin as sirolimus for transplant rejection and other uses). The combination is not approved for anything. The lifespan result is in mice and lacks a contemporaneous rapamycin-alone comparison. | FDA-approved (Rapamune); longevity use is off-label and investigational |
| Half-life | Not reported | ~60 hours |
| Molecular weight | Not reported | 914.2 Da |
| Mechanism | Rapamycin inhibits mTORC1, and at the doses used in mice lowers cancer incidence, alters immune function and shifts metabolism in ways that are distinct from dietary restriction. Metformin inhibits mitochondrial complex I, activates AMPK in some tissues and lowers hepatic glucose output. The rationale for combining them was that metformin might blunt the glucose intolerance and insulin resistance rapamycin causes in mice, and that the two act on partly separate nutrient-sensing pathways. The ITP paper reports the lifespan outcome and does not test that mechanism; it did not include a rapamycin-alone arm, so it cannot say whether metformin added anything, and the mechanistic case for synergy rests on inference from each drug's separate literature. In people there are no data on the combination. Each drug's human pharmacology is on its own page. | Inhibits the mTOR pathway, mimicking aspects of caloric restriction and enhancing autophagy and cellular maintenance. |
| Human studies cited | 2 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved (for its labeled use), prescription only |
Frequently asked questions
What is the difference between Metformin plus rapamycin and Rapamycin?
Metformin plus rapamycin: Fed together from 9 months, metformin 1,000 ppm and rapamycin 14 ppm extended median mouse lifespan 23 percent in both sexes. Metformin alone in the same cohort did nothing, there was no rapamycin-alone arm to compare against, and the ITP's own paper says the apparent extra benefit over historical rapamycin cohorts did not reach significance by its protocol test. Rapamycin: An FDA-approved mTOR inhibitor that extends lifespan in animals and is widely studied off-label at low, intermittent doses for longevity.
Which has stronger research evidence, Metformin plus rapamycin or Rapamycin?
This database does not grade compounds. It counts what was run in people: 2 of the 8 studies cited on the Metformin plus rapamycin profile were human work, against 2 of 3 for Rapamycin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Metformin plus rapamycin and Rapamycin FDA-approved?
Metformin plus rapamycin: Both drugs are FDA-approved for other indications (metformin for type 2 diabetes, rapamycin as sirolimus for transplant rejection and other uses). The combination is not approved for anything. The lifespan result is in mice and lacks a contemporaneous rapamycin-alone comparison.. Rapamycin: FDA-approved (Rapamune); longevity use is off-label and investigational.
Related posts
Blog articles that cover Metformin plus rapamycin or Rapamycin, newest first.
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 8, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 8, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.